KeenMind is a clinically proven extract of Bacopa monnieri that promotes memory, recall, concentration, and mental clarity in adults and children. It is the result of 30 years of research by the Central Drug Research Institute in India. Double-blind studies in Australia found that after 12 weeks, KeenMind significantly improved speed of learning, memory consolidation, and mental processing with no side effects. It contains optimum levels of bacosides and other constituents that have cognitive benefits and is the only Bacopa product to meet these standards.

1. www.flordis.com.au PO Box 1027, Crows Nest NSW 1585, Australia Tel + 61 2 9431 7200clinically proven natural medicines
KeenMind®
The world’s leading researched
Bacopa monnieri
Promote memory and recall,
concentration and mental clarity in
adults & children
4
3,5
* maximal effects evident after 12 weeks treatment in subjects aged 18 to 60 years
** ability to hold and use information “online” after 90 days treatment in subjects
aged 40 to 65 years
References
1. Singh, R.H . & Sing, L., Res. Ayur. Siddha 1980, 1:133-148.
2. Sharma et al, J. Res.Educ. Indian Med. 1987 1:12.
3. Stough et al, Psychopharmacology (Berl.). 2001, 156(4): 481-484.
4. Roodenrys et al 2002. Neuropsychopharmacology 27 (2):279-281
5. Stough et al, Phytotherapy Res. 2008 DOI: 10.1002/ptr.2537
Cognitive function P value
Improved ‘working memory’** <0.035
Improved speed of learning* <0.042
Improved memory consolidation* <0.042
Improved speed of visual <0.018
information processing*
Improved speed of early <0.05
information processing*
Decreased forgetting rate* <0.03
(CDRI 08)
1,2,3,4,5
Mechanism of Action
Evidence suggests modulation of the
cholinergic system and/or antioxidant and
metal chelating effects
Actions include anti-inflammatory and
neuro protective effects, relaxant
properties in blood vessels and adaptogenic
activity
KeenMind is unique
Studies indicate cognitive effects are
achieved with no clinically relevant
side effects
Safe for use in children and adults,
including the elderly
Children and students – to facilitate learning
Teachers, lecturers and practitioners –
to increase mental performance
People with high demand careers
Elderly – to delay cognitive decline
The result of 30 years of meticulous
research and development by the
Indian government’s Central Drug
Research Institute (CDRI)
The only Bacopa to contain optimum
levels of the therapeutic bacosides
A and B (55%) as well as other
therapeutically relevant constituents
To be taken with breakfast.
Adults: 2 capsules daily
Children: 1 capsule daily
Ideal uses for KeenMind
Safety
Dosage
KeenMind (CDRI 08)
is clinically proven to:
KeenMind is clinically proven in
double-blind placebo-controlled
Australian studies

2. Background to KeenMind
Bacopa monnieri (Bacopa) is a perennial creeping plant found
in wet, damp and marshy areas in India. Bacopa has been
mentioned in the religious, social and medical treatises of India
since 3000 B.C. Its use as a memory enhancing agent can be
traced back to 1500 B.C. Classical Ayurveda identified the
medicinal properties of Bacopa as being beneficial for mental
disorders leading to memory impairment and as being
efficacious even in total loss of memory.
Bacopa has been used in traditional Ayurvedic medicine for
various indications including memory decline, inflammation,
pain, pyrexia, epilepsy and as a sedative.
Unique Formulation
KeenMind is the Bacopa extract which has been extensively
investigated by the Indian government’s Central Drug
Research Institute (CDRI). Phytochemical analysis of this plant
was first conducted at the CDRI in 1963 and 1965 . As with
most herbal medicines, a complex mix of constituents is
needed for their therapeutic action, as was evidenced in the
case of Bacopa. Many active constituents were identified
including alkaloids, saponins, D-mannitol, betulic acid,
β-sitosterol and stigmasterols, and the steroidal saponins,
specifically Bacosides A and B which are believed to be
essential for the clinical efficacy of this herb. The CDRI
developed the unique standardised extract of Bacopa monnieri
KeenMind (CDRI 08). This broad-spectrum extract is unique as
it contains, along with other non-bacoside active components,
optimum therapeutic levels of bacosides (55% ± 5%); levels
which have not been identified in any other Bacopa product.
While Bacopa has been reported to have many actions, it is
the memory enhancing effects which have attracted most
attention and pharmacological studies have supported these
historical anecdotal claims for Bacopa.
Mode of Action
Although the exact mechanism of action of Bacopa on
cognitive processes has not yet been determined, evidence
suggests that it may modulate the cholinergic system and/or
have antioxidant and metal chelating effects. Other purported
actions include antiinflammatory, neuroprotective, anxiolytic
and antidepressant effects as well as relaxant properties in
blood vessels and adaptogenic activity.
Clinical Studies
Over the last 30 years the CDRI has researched and developed
the modern use of Bacopa. The scientific evidence for the
memory enhancing effects of Bacopa is based on pre-clinical
studies, and confirmed in numerous clinical trials conducted
in humans. Results include:
• Enhanced memory, reduced anxiety and mental
fatigue and increased work output for patients
with anxiety neurosis
• Enhanced memory and improved learning ability
for children
The first double blind placebo-controlled trial for KeenMind
was published in 2001 . This study was conducted in Australia
KeenMind (CDRI 08)
Special extract of Bacopa monnieri
®
Andrea Zangara
BSc (Clinical Psychology)
Research Scholar, Medicinal Plant Research Centre, Newcastle University, UK
Research Fellow, Brain Sciences Institute, Swinburne University, AU
Flordis International Business Development Manager
by Professor Con Stough and colleagues at Swinburne
University to investigate the memory enhancing effects in
46 healthy subjects aged between 18 and 60 years. Results
showed significantly improved speed of visual information
processing, learning rate and memory consolidation, and
decreased anxiety; maximal effects were evident after 12
weeks. Roodenrys and colleagues replicated the memory
enhancing effects of KeenMind in 76 participants aged between
40 and 65 years . They reported a significant decrease in the
rate of forgetting newly acquired information after 90 days of
treatment in a sample of older individuals than previously used
by Stough and colleagues (2001).
The most recent study on KeenMind was published in the
Journal of Phytotherapy in August 2008 . This study of 62
healthy participants was conducted at the Brain Sciences
Institute at Swinburne University in Melbourne Australia.
Cognitive function tests commonly used in dementia trials
(Cognitive Drug Research (CDR) computerised assessment
system) were used to assess the effects of KeenMind compared
to a placebo, in a randomised double blind placebo controlled
trial (the gold standard in clinical research). After 90 days of
treatment with 2 capsules of KeenMind the participants had
significantly improved performance on “working memory”
(the ability to hold information “online” in the brain and
actually do something with that information) and “visual
information processing” (a measure of the ability to sustain
attention). Slowed information processing is one of the most
prominent cognitive deficits in the elderly.
KeenMind is the result of 3 decades of intensive research
worldwide and now 3 clinical studies have confirmed the
potential of this natural product. These rigorously designed
trials have proven that KeenMind improves memory and other
measures of brain function. KeenMind is a ‘rising star’ to be
closely followed in the ongoing research of evidence-based
botanicals for brain health.
Safety
In the studies conducted it appears that the cognitive effects
of KeenMind are achieved with no clinically relevant side
effects, even in children and elderly participants.
Dosage
The capsules are best taken with breakfast. Adults take
2 capsules daily and children can take one capsule daily.
Key clinical information on KeenMind
®
The world’s leading researched and clinically proven Bacopa
monnieri for use in adults and children
Promotes memory and recall, concentration and mental
clarity, clinically proven in Australian published studies
The result of 30 years of meticulous research and
development by the Indian government’s, Central Drug
Research Institute (CDRI)
A unique broad-spectrum extract of Bacopa, and the only
Bacopa to contain optimum levels of the therapeutic
bacosides at 55% ± 5% as well as other therapeutically
relevant constituents; these standards are not available in
any other Bacopa product
1. Chatterjee et al, Ind. J. Chem., 1963, 1:212-215.
2. Chatterjee et al, Ind. J. Chem., 1965, 3:24-29.
3. Singh, R.H . & Sing, L., Res. Ayur. Siddha 1980, 1:133-148.
4. Sharma et al, J. Res.Educ. Indian Med. 1987 1:12.
5. Stough et al, Psychopharmacology (Berl.). 2001, 156(4):481-484.
6. Roodenrys et al 2002. Neuropsychopharmacology 27(2):279-281
7 Stough et al, Phytotherapy Res. 2008 DOI: 10.1002/ptr.2537
References
1 2
3
4
5
6
7